{"prompt": "['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-004', '(Sanofi Genzyme EFC14769)', '27 Jun 2018', 'Table 1:', 'Schedule of Assessments', 'Treatment Period', 'AT', 'Onset', 'Efficacy Period', 'F/Ub,c', 'Period', 'EOS/', 'EOT', 'ETa,b', 'Study Visit (Month)', 'Study Day (Visit Window)', 'Informed Consent/Assent', 'Medical Historyd', 'Demographics', 'Inclusion/Exclusion Criteria', 'Randomization', 'eDiary Training', 'X', 'Physical Examination8', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Body Weight and Heighth', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Vital Signs', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', \"12-Lead ECG'\", 'X', 'X', 'FibroScan OR FibroTest/APRI', 'TG Level k,1', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Coagulation', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Nijmegen-Modified Bethesda', 'X', 'Xm', 'Assay (Inhibitor Status)', 'AT Activity Levelk.n,', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'FVIII / FIX Levels*', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Property of the Sanofi Group - strictly confidential', '11', '(electronic 1.0)']['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-004', '(Sanofi Genzyme EFC14769)', '27 Jun 2018', 'Table 1:', 'Schedule of Assessments', 'Treatment Period', 'AT', 'Onset', 'Efficacy Period', 'F/Ub,c', 'Period', 'EOS/', 'EOT', 'ETa,b', 'Study Visit (Month)', 'Study Day (Visit Window)', 'Thrombophilia Screening', 'Serum Chemistry', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Liver Function TestsP', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Anti-Drug', 'X', 'X', 'X', 'Xm', 'Hematology', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Hepatic TestsP', 'X', 'Exploratory Biomarkers*', 'X', 'X', 'Exploratory Circulating RNA', 'X', 'X', 'X', '(Optional)*', 'Exploratory DNA Sample', 'X', '(Optional)', 'Plasma PKK,', 'X', 'X', 'X', 'X', 'Urinalysis', 'X', 'Urine Collection for', 'Biomarkers*', 'X', 'X', 'HJHS', 'X', 'X5', 'Patient Resource Use5', 'X', 'X5', 'EQ-5D5', 'X', 'X5', 'Property of the Sanofi Group - strictly confidential', '12', '(electronic 1.0)']['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-004', '(Sanofi Genzyme EFC14769)', '27 Jun 2018', 'Table 1:', 'Schedule of Assessments', 'Treatment Period', 'AT', 'Onset', 'Efficacy Period', 'F/Ub,c', 'Period', 'EOS/', 'EOT', 'ETa,b', 'Study Visit (Month)', 'Study Day (Visit Window)', 'Haem-A-QOL / Haemo-QOL5', 'X', 'X5', 'HAL / pedHAL5', 'Xs', 'TSQM-95', 'X5', 'Fitusiran Administration', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', '(Fitusiran arm only)', 'Patient Education Module', 'X', 'Training', 'Bleed Management Review', 'Review with patient at each visit and contact every 2 weeks between visits', 'Bleeding Episodes/eDiary\"', 'Review with patient at each visit and contact every 2 weeks between visits', 'Perioperative Assessment', 'Continuous', 'Adverse Events\"', 'Continuous', 'Concomitant Medications*', 'Continuous', 'Abbreviations: AEs = adverse events; AT = antithrombin; ECG = electrocardiogram; eDiary = electronic diary; EOS = end of study; EOT = end of treatment; ET = early-', 'termination; FVIII = factor VIII; FIX = factor IX; F/U = follow-up; Haem-A-QOL = Hemophilia Quality of Life Questionnaire for Adults; Haemo-QOL = Hemophilia Quality of', 'Life Questionnaire for children and adolescents; HAL = Hemophilia Activities List; HJHS = Hemophilia Joint Health Score; IMP = Investigational medicinal product; Min =', 'minute; pedHAL = pediatric HAL; PK = pharmacokinetics; TG = thrombin generation; TSQM-9 = Treatment Satisfaction Questionnaire for Medication', 'Note:', 'See Section 7 for study assessment instructions.', 'Any Screening assessments performed within 7 days prior to baseline do not need to be repeated at the Baseline visit.', 'Property of the Sanofi Group - strictly confidential', '13', '(electronic 1.0)']\n\n###\n\n", "completion": "END"}